New Triple-Action Cancer Drug Shows Major Promise in Shrinking Tumours

New Triple-Action Cancer Drug Shows Major Promise in Shrinking Tumours
………………

Doctors have hailed “incredibly encouraging” results from a clinical trial showing that a new triple-action drug can shrink head and neck cancer tumours within six weeks, The Guardian reported. The treatment, using an injection called amivantamab, was tested on patients with recurrent or metastatic cancers that had stopped responding to standard therapies such as immunotherapy and chemotherapy.

Presented at the European Society for Medical Oncology conference in Berlin, the Orig-AMI 4 trial involved 86 patients across 11 countries. Early results showed that 76% of participants saw their tumours shrink or stop growing, with most side effects described as mild to moderate. Average progression-free survival was 6.8 months.

Professor Kevin Harrington of the Institute of Cancer Research said the findings could signal a “real shift” in treatment, noting that the drug is delivered via a quick under-skin injection rather than lengthy infusions.

Amivantamab works by blocking two cancer growth pathways, EGFR and MET, while activating the immune system to attack tumours. Researchers believe the therapy could make cancer care more effective and convenient, potentially allowing future administration in outpatient clinics or even at home.